NVS Stock Recent News
NVS LATEST HEADLINES
NVS' Cosentyx fails to meet its primary goal in a phase III study for giant cell arteritis, despite favorable safety data.
Novartis said on Thursday that its Cosentyx drug had failed in a late-stage trial on adults with giant cell arteritis (GCA), a condition characterised by inflammation of the arteries.
The GCAptAIN study did not meet its primary endpoint of sustained remission at Week 52 in adults with newly diagnosed or relapsing GCA1 Safety in GCA patients was consistent with known safety profile of Cosentyx® (secukinumab)1 EAST HANOVER, N.J. , July 3, 2025 /PRNewswire/ -- Novartis today announced top-line results from the Phase III GCAptAIN study evaluating Cosentyx® (secukinumab) in adults with newly diagnosed or relapsing giant cell arteritis (GCA).
Basel, July 03, 2025 – Novartis today announced top-line results from the Phase III GCAptAIN study evaluating Cosentyx® (secukinumab) in adults with newly diagnosed or relapsing giant cell arteritis (GCA).
As Wall Street faces mixed moves in July, NVS, ALG, MT, BILI and STRL stand out as low-leverage stocks to weather volatility.
Novartis (NVS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
As you look at the stock markets around the world, it's always a balance of trying to decide when is the right time to buy.
The Investment Committee give you their top stocks to watch for the second half.
ProFound to receive $25M in upfront and near-term milestone payments with a potential value from downstream milestones of $750M per target
Basel, June 25, 2025 – Novartis today announced that it has successfully completed its acquisition of Regulus Therapeutics Inc. (“Regulus”). With the completion of the acquisition, shares of common stock, par value $0.001 per share (the “Shares”), of Regulus, have ceased trading on the Nasdaq Stock Market LLC and Regulus is now an indirect wholly owned subsidiary of Novartis.